Relative to the triple-negative BC subtype, in the era of immunotherapy for early and advanced disease, the role of ATM mutations in predicting treatment efficacy and good or poor response to immune checkpoint inhibitors, such as PD1/PDL1 inhibitors, could be interesting. Here, CD274 is linked to breast cancer.